- Home
- TOP vs VERU Comparison
TOP vs VERU Comparison
Compare TOP & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOP
- VERU
- Stock Information
- Founded
- TOP 2015
- VERU 1971
- Country
- TOP Singapore
- VERU United States
- Employees
- TOP N/A
- VERU N/A
- Industry
- TOP Investment Bankers/Brokers/Service
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- TOP Finance
- VERU Health Care
- Exchange
- TOP Nasdaq
- VERU Nasdaq
- Market Cap
- TOP 43.0M
- VERU 40.6M
- IPO Year
- TOP 2022
- VERU 1990
- Fundamental
- Price
- TOP $1.03
- VERU $2.17
- Analyst Decision
- TOP
- VERU Strong Buy
- Analyst Count
- TOP 0
- VERU 2
- Target Price
- TOP N/A
- VERU $25.00
- AVG Volume (30 Days)
- TOP 60.9K
- VERU 191.3K
- Earning Date
- TOP 08-13-2025
- VERU 12-15-2025
- Dividend Yield
- TOP N/A
- VERU N/A
- EPS Growth
- TOP N/A
- VERU N/A
- EPS
- TOP N/A
- VERU N/A
- Revenue
- TOP $3,329,256.00
- VERU $16,886,419.00
- Revenue This Year
- TOP N/A
- VERU N/A
- Revenue Next Year
- TOP N/A
- VERU N/A
- P/E Ratio
- TOP N/A
- VERU N/A
- Revenue Growth
- TOP N/A
- VERU 337.24
- 52 Week Low
- TOP $1.00
- VERU $2.11
- 52 Week High
- TOP $3.33
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- TOP 34.31
- VERU 25.21
- Support Level
- TOP $1.03
- VERU $2.11
- Resistance Level
- TOP $1.07
- VERU $2.57
- Average True Range (ATR)
- TOP 0.05
- VERU 0.20
- MACD
- TOP -0.00
- VERU -0.03
- Stochastic Oscillator
- TOP 20.37
- VERU 9.33
About TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.